Esra Kaya Kılıç1, Cemal Bulut2, Meliha Çağla Sönmezer3, Özlem Ozel4, Çiğdem Ataman Hatipoğlu5, Günay Tuncer Ertem6, Necla Tülek7, Sami Kınıklı8. 1. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Ankara Training and Research Hospital, Ankara, Turkey. esrakayakilic@yahoo.com.tr. 2. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Gülhane Training and Research Hospital, Ankara, Turkey. 3. Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University Ankara, Turkey. caglasonmezer@hotmail.com. 4. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Ankara Training and Research Hospital, Ankara, Turkey. ozlemozel@hotmail.com. 5. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Ankara Training and Research Hospital, Ankara, Turkey. cigdemhatip@yahoo.com. 6. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Ankara Training and Research Hospital, Ankara, Turkey. tuncergunay@yahoo.com. 7. Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Atılım University Ankara, Turkey. ntulek@gmail.com. 8. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Ankara Training and Research Hospital, Ankara, Turkey. esrakayakilic@gmail.com.
Abstract
INTRODUCTION: Linezolid is a synthetic antimicrobial agent with a broad spectrum of activity against virtually all Gram-positive bacteria. Although linezolid is generally well tolerated, the prolonged use of linezolid can lead to myelosuppression, including neutropenia, thrombocytopenia, and anemia. The aim of this study was investigating the risk factors for thrombocytopenia in patients who received linezolid therapy. METHODOLOGY: This retrospective study was performed on patients who received linezolid therapy between July 2007 and December 2017. Thrombocytopenia was defined as either a platelets count of < 100×109/L or a 25% reduction from the baseline platelet count. RESULTS: A total of 371 patients, (198 (53%) male and 173(47%) female were included into the study. Mean duration of therapy was 12.81 ± 5.19 days. Linezolid-induced thrombocytopenia was detected in a total of 111 patients. Using the univariate analysis advanced sex, serum urea concentration, baseline platelet level and low eGFR value were found to be risk factors for linezolid associated thrombocytopenia (p < 0.05). According to a multivariate analysis, patients undergoing carbapenem treatment combination therapy (p = 0.003) and with a baseline platelet level of < 200×109/L (p = 0.00) were found to have a high risk of developing thrombocytopenia. CONCLUSIONS: Several factors may influence of linezolid associated thrombocytopenia. Platelet count should be monitored during therapy and thrombocytopenia should be kept in mind in patients with baseline platelet level of < 200×109/L, low eGFR, linezolid-carbapenem combination therapy. Copyright (c) 2019 Esra Kaya Kilic, Cemal Bulut, Meliha Cagla Sonmezer, Ozlem Ozel, Cigdem Ataman Hatipoglu, Gunay Tuncer Ertem, Necla Tulek, Sami Kinikli.
INTRODUCTION:Linezolid is a synthetic antimicrobial agent with a broad spectrum of activity against virtually all Gram-positive bacteria. Although linezolid is generally well tolerated, the prolonged use of linezolid can lead to myelosuppression, including neutropenia, thrombocytopenia, and anemia. The aim of this study was investigating the risk factors for thrombocytopenia in patients who received linezolid therapy. METHODOLOGY: This retrospective study was performed on patients who received linezolid therapy between July 2007 and December 2017. Thrombocytopenia was defined as either a platelets count of < 100×109/L or a 25% reduction from the baseline platelet count. RESULTS: A total of 371 patients, (198 (53%) male and 173(47%) female were included into the study. Mean duration of therapy was 12.81 ± 5.19 days. Linezolid-induced thrombocytopenia was detected in a total of 111 patients. Using the univariate analysis advanced sex, serum urea concentration, baseline platelet level and low eGFR value were found to be risk factors for linezolid associated thrombocytopenia (p < 0.05). According to a multivariate analysis, patients undergoing carbapenem treatment combination therapy (p = 0.003) and with a baseline platelet level of < 200×109/L (p = 0.00) were found to have a high risk of developing thrombocytopenia. CONCLUSIONS: Several factors may influence of linezolid associated thrombocytopenia. Platelet count should be monitored during therapy and thrombocytopenia should be kept in mind in patients with baseline platelet level of < 200×109/L, low eGFR, linezolid-carbapenem combination therapy. Copyright (c) 2019 Esra Kaya Kilic, Cemal Bulut, Meliha Cagla Sonmezer, Ozlem Ozel, Cigdem Ataman Hatipoglu, Gunay Tuncer Ertem, Necla Tulek, Sami Kinikli.
Authors: Francesca Conradie; Tatevik R Bagdasaryan; Sergey Borisov; Pauline Howell; Lali Mikiashvili; Nosipho Ngubane; Anastasia Samoilova; Sergey Skornykova; Elena Tudor; Ebrahim Variava; Petr Yablonskiy; Daniel Everitt; Genevieve H Wills; Eugene Sun; Morounfolu Olugbosi; Erica Egizi; Mengchun Li; Alda Holsta; Juliano Timm; Anna Bateson; Angela M Crook; Stella M Fabiane; Robert Hunt; Timothy D McHugh; Conor D Tweed; Salah Foraida; Carl M Mendel; Melvin Spigelman Journal: N Engl J Med Date: 2022-09-01 Impact factor: 176.079
Authors: Joyce Oi Yan Chan; Marie Moullet; Beth Williamson; Rosalinda H Arends; Venkatesh Pilla Reddy Journal: Front Pharmacol Date: 2022-06-06 Impact factor: 5.988